Vegfr1 (** - Multi-kinase inhibitors targeting VEGFR1 include: Sutent (sunitinib), Nexavar (sorafenib), Votrient (pazopanib), Stivarga (regorafenib) - VEGF trap agents: Zaltrap (aflibercept) **)

Description

Vegfr1 is not a drug itself, but a protein (Vascular Endothelial Growth Factor Receptor 1) that plays a role in the growth of new blood vessels, which tumors need to grow and spread. Some cancer treatments target this protein or related proteins (like Vegfr2) to stop angiogenesis. The clinical trial you mentioned (NCT00677612) is investigating a vaccine approach using peptides derived from Vegfr1 and Vegfr2. This vaccine is designed to stimulate the body's immune system (specifically cytotoxic T lymphocytes or CTLs) to recognize and attack cancer cells that express these receptors. The trial combines this vaccine with standard chemotherapy (Tegafur/Uracil/Folinate) to assess safety, clinical response, and immune response in patients with colorectal cancer. It's important to note that this is an investigational approach, meaning it is still being studied and is not yet an approved treatment for colorectal cancer.

Mechanism of Action

The trial (NCT00677612) uses peptides derived from Vegfr1 and Vegfr2. These peptides are injected as a vaccine, along with an adjuvant (Montanide ISA 51) to boost the immune response. The goal is to activate the patient's immune system, specifically T cells, to recognize Vegfr1 and Vegfr2 as targets on cancer cells. By stimulating this immune response, the vaccine aims to help the body fight the cancer. The trial is investigating whether this approach can induce a tumor-specific immune response and potentially slow or stop tumor growth.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials